NCT03833999View on ClinicalTrials.gov

Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

June 27, 2019

Study Completion Date

June 27, 2019

Conditions
Motility Disorder of IntestineOndansetronSmall Bowel Water
Interventions
DRUG

Ondansetron 8mg

ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting

DIAGNOSTIC_TEST

abdominal MRI

serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3

DRUG

Lactulose

Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day

DRUG

Placebo oral capsule

overcoated placebo tablet, identical to the ondansetron

Trial Locations (1)

NG7 2UH

University of Nottingham, Nottingham

All Listed Sponsors
lead

University of Nottingham

OTHER

NCT03833999 - Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea | Biotech Hunter | Biotech Hunter